SXTP insider filings
60 DEGREES PHARMACEUTICALS, INC. — 27 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-06-15. Screen SXTP transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for SXTP between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — 60 DEGREES PHARMACEUTICALS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-15 | 4 | DOW GEOFFREY S — President and CEO, Director | Purchase (P): 7,350 @ $1.38 | EDGAR |
| 2025-12-16 | 4 | DOW GEOFFREY S — President and CEO, Director | Purchase (P): 9,670 @ $0.80 | EDGAR |
| 2025-12-12 | 4 | DOW GEOFFREY S — President and CEO, Director | Purchase (P): 9,350 @ $0.95 · Purchase (P): 3,613 @ $0.92 | EDGAR |
| 2025-09-15 | 4 | DOW GEOFFREY S — President and CEO, Director | Grant/award (A): 7,201 @ $1.39 | EDGAR |
| 2025-08-14 | 4 | Landon Kristen — Chief Operating Officer | Grant/award (A): 4,167 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Landon Kristen — Chief Operating Officer | Grant/award (A): 4,540 @ $0 | EDGAR |
| 2025-06-09 | 4 | DOW GEOFFREY S — President and CEO, Director | Grant/award (A): 4,376 @ $2.99 | EDGAR |
| 2025-06-05 | 4 | XU CHERYL — Director | Purchase (P): 3,000 @ $2.87 · Purchase (P): 2,000 @ $2.90 | EDGAR |
| 2025-01-24 | 4 | DOW GEOFFREY S — President and CEO, Director | Grant/award (A): 525,000 (derivative) @ $0 | EDGAR |
| 2025-01-24 | 4 | MILLER TYRONE — CFO | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-01-21 | 4 | DOW GEOFFREY S — President and CEO, Director | Grant/award (A): 14,394 @ $0 | EDGAR |
| 2025-01-21 | 4 | MILLER TYRONE — CFO | Grant/award (A): 11,626 @ $0 | EDGAR |
| 2024-12-18 | 4 | XU CHERYL — Director | Purchase (P): 2,500 @ $1.85 · Purchase (P): 2,500 @ $1.80 · Purchase (P): 1,500 @ $1.60 · Purchase (P): 1,500 @ $1.58 · Purchase (P): 1,500 @ $1.55 · Purchase (P): 1,500 @ $1.52 · +1 more | EDGAR |
| 2024-12-09 | 4 | DOW GEOFFREY S — President and CEO, Director | Purchase (P): 17,549 @ $1.11 · Purchase (P): 20,579 @ $1.20 · Purchase (P): 35,823 @ $1.27 | EDGAR |
| 2024-11-21 | 4 | DOW GEOFFREY S — President and CEO, Director | Purchase (P): 2,500 @ $0.90 · Purchase (P): 1,000 @ $0.92 · Purchase (P): 3,500 @ $0.91 | EDGAR |
| 2024-09-11 | 4 | XU CHERYL — Director | Purchase (P): 5,000 @ $1.70 | EDGAR |
| 2024-05-21 | 4 | XU CHERYL — Director | Option exercise (M): 2,000 @ $0.22 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | TOOVEY STEPHEN — Director | Grant/award (A): 4,000 @ $0.22 · Grant/award (A): 4,000 (derivative) @ $0 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | MILLER TYRONE — CFO | Grant/award (A): 60,000 @ $0.27 · Grant/award (A): 15,000 @ $0.22 · Grant/award (A): 75,000 (derivative) @ $0 · Option exercise (M): 60,000 (derivative) @ $0 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | FIELD PAUL — Director | Option exercise (M): 4,000 @ $0.22 · Grant/award (A): 4,000 (derivative) @ $0 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | DOW GEOFFREY S — President and CEO, Director | Option exercise (M): 68,000 @ $0.27 · Option exercise (M): 17,000 @ $0.22 · Grant/award (A): 85,000 (derivative) @ $0 · Option exercise (M): 68,000 (derivative) @ $0 · Option exercise (M): 17,000 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | Allen Charles W — Director | Option exercise (M): 4,000 @ $0.22 · Grant/award (A): 4,000 (derivative) @ $0 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Knight Therapeutics Inc KNIGHT THERAPEUTICS INTERNATIONAL SA | Conversion (C): 45,560 @ $4.75 · Conversion (C): 2,162 @ $0 | EDGAR |
| 2024-02-02 | 4 | DOW GEOFFREY S — President and CEO, Director | Purchase (P): 25,974 @ $0.38 · Purchase (P): 25,974 (derivative) @ $0.01 | EDGAR |
| 2024-02-02 | 4 | XU CHERYL — Director | Purchase (P): 200,000 @ $0.38 · Option exercise (M): 2,000 · Purchase (P): 200,000 (derivative) @ $0.01 | EDGAR |
| 2023-07-12 | 4 | MILLER TYRONE — Chief Financial Officer | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2023-07-12 | 4 | DOW GEOFFREY S — President and CEO, Director, 10% owner | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — 60 DEGREES PHARMACEUTICALS, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-20 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 7.01 — Regulation FD Disclosure 8.01 — Other Events | EDGAR |
| 2026-11-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-27 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-23 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-06 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-14 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-09-08 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-08-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-20 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SXTP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs